Subject to change.
Subject to change.
Michael joined Roche Diagnostics in 2006 and has been Lifecycle Leader for Digital Pathology since October 2015. In this role, he leads the Digital Pathology team in Santa Clara, California to develop and commercialize the Digital Pathology portfolio of products and technology for Roche. Michael also is a Past President of the Digital Pathology Association and has been a member of the DPA Board of Directors since 2015. Michael has held a number of sales and marketing leadership roles at Roche and is passionate about the opportunity to transform cancer diagnostics with Digital Pathology.
Digital pathology adoption and AI image analysis show significant potential, but return on investment (ROI) remains a challenge. The lack of reimbursement for FDA-cleared digital pathology (DP) solutions is a major barrier to widespread adoption. The DPA Reimbursement Task Force has a mission to 'To define and shape the pathway to reimbursement for digital pathology solutions enabling broad market access and delivery of value to patients and stakeholders. This session will provide an update on the key work of the DPA Reimbursement Task Force and provide a detailed look into the framework for DP AI reimbursement that the task force is pursuing. In addition, we will hear from experts on key changes to the reimbursement landscape in the US and important trends that are shaping how these solutions are being brought to the market.
Learning Objectives: